LIVIVO - Search results -

Search results

Result 1 - 8 of total 8

Search options

Article ; Online: Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials.

Tobe, Sheldon W / Mavrakanas, Thomas A / Bajaj, Harpreet S / Levin, Adeera / Tangri, Navdeep / Slee, April / Neuen, Brendon L / Perkovic, Vlado / Mahaffey, Kenneth W / Rapattoni, Wally / Ang, Fernando G

Diabetes care

2024 Volume 47, Issue 3, Page(s) 501–507

Abstract: Objective: The study was undertaken because it was unknown whether the duration of type 2 diabetes modifies the effects of sodium-glucose cotransporter 2 inhibitor canagliflozin on cardiovascular (CV) and kidney outcomes.: Research design and methods!# ...

Abstract	Objective: The study was undertaken because it was unknown whether the duration of type 2 diabetes modifies the effects of sodium-glucose cotransporter 2 inhibitor canagliflozin on cardiovascular (CV) and kidney outcomes. Research design and methods: This post hoc analysis of the Canagliflozin Cardiovascular Assessment Study (CANVAS) Program (N = 10,142) and Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE) trial (N = 4,401) evaluated hazard ratios and 95% CIs using Cox proportional hazards for the effects of canagliflozin on CV and kidney outcomes, including progression and regression of albuminuria over 5-year intervals of disease duration. Results: Canagliflozin had ranges of benefit across intervals of diabetes duration, with no heterogeneity for major adverse CV events, CV death or heart failure hospitalization, and kidney failure requiring therapy or doubling serum creatinine. Furthermore, canagliflozin reduced albuminuria progression and increased albuminuria regression with no interaction across all diabetes duration subgroups. Conclusions: Our findings suggest that earlier treatment with canagliflozin confers consistent cardiorenal benefits to individuals with type 2 diabetes.
MeSH term(s)	Humans ; Canagliflozin/therapeutic use ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use ; Albuminuria/drug therapy ; Cardiovascular Diseases ; Kidney
Chemical Substances	Canagliflozin (0SAC974Z85) ; Sodium-Glucose Transporter 2 Inhibitors
Language	English
Publishing date	2024-01-22
Publishing country	United States
Document type	Meta-Analysis ; Journal Article
ZDB-ID	441231-x
ISSN	1935-5548 ; 0149-5992
ISSN (online)	1935-5548
ISSN	0149-5992
DOI	10.2337/dc23-1450
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1434: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 365: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial.

Sharma, Abhinav / Razaghizad, Amir / Joury, Abdulaziz / Levin, Adeera / Bajaj, Harpreet S / Mancini, G B John / Wong, Norman C / Slee, April / Ang, Fernando G / Rapattoni, Wally / Neuen, Brendon L / Arnott, Clare / Perkovic, Vlado / Mahaffey, Kenneth W

Journal of the American Heart Association

2024 Volume 13, Issue 3, Page(s) e031586

Abstract: Background: This study evaluated the effects of canagliflozin in patients with type 2 diabetes with and without prevalent cardiovascular disease (secondary and primary prevention).: Methods and results: This was a pooled participant-level analysis of ...

Abstract	Background: This study evaluated the effects of canagliflozin in patients with type 2 diabetes with and without prevalent cardiovascular disease (secondary and primary prevention). Methods and results: This was a pooled participant-level analysis of the CANVAS (Canagliflozin Cardiovascular Assessment Study) Program and CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) trial. The CANVAS Program included participants with type 2 diabetes at elevated cardiovascular risk, whereas the CREDENCE trial included participants with type 2 diabetes and albuminuric chronic kidney disease. Hazard ratios (HRs) with interaction terms were obtained from Cox regression models to estimate relative risk reduction with canagliflozin versus placebo across the primary and secondary prevention groups. We analyzed 5616 (38.9%) and 8804 (61.1%) individuals in the primary and secondary prevention subgroups, respectively. Primary versus secondary prevention participants were on average younger (62.2 versus 63.8 years of age) and more often women (42% versus 31%). Canagliflozin reduced the risk of major adverse cardiovascular events (HR, 0.84 [95% CI, 0.76-0.94]) consistently across primary and secondary prevention subgroups ( Conclusions: Canagliflozin reduced cardiovascular and kidney outcomes with no statistical evidence of heterogeneity for the treatment effect across the primary and secondary prevention subgroups in the CANVAS Program and CREDENCE trial. Although studies on the optimal implementation of canagliflozin within these populations are warranted, these results reinforce canagliflozin's role in cardiorenal prevention and treatment in individuals with type 2 diabetes. Registration: URL: https://www.clinicaltrials.gov; Unique identifiers: NCT01032629, NCT01989754, NCT02065791.
MeSH term(s)	Humans ; Female ; Canagliflozin/therapeutic use ; Canagliflozin/pharmacology ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/diagnosis ; Diabetes Mellitus, Type 2/drug therapy ; Sodium-Glucose Transporter 2 Inhibitors/adverse effects ; Treatment Outcome ; Kidney ; Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/prevention & control ; Cardiovascular Diseases/drug therapy ; Renal Insufficiency, Chronic/complications ; Renal Insufficiency, Chronic/diagnosis ; Renal Insufficiency, Chronic/epidemiology
Chemical Substances	Canagliflozin (0SAC974Z85) ; Sodium-Glucose Transporter 2 Inhibitors
Language	English
Publishing date	2024-01-19
Publishing country	England
Document type	Journal Article
ZDB-ID	2653953-6
ISSN	2047-9980 ; 2047-9980
ISSN (online)	2047-9980
ISSN	2047-9980
DOI	10.1161/JAHA.123.031586
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial.

Yi, Tae Won / Wong, Michelle M Y / Neuen, Brendon L / Arnott, Clare / Poirier, Paul / Seufert, Jochen / Slee, April / Rapattoni, Wally / Ang, Fernando G / Wheeler, David C / Mahaffey, Kenneth W / Perkovic, Vlado / Levin, Adeera

Diabetes, obesity & metabolism

2023 Volume 25, Issue 7, Page(s) 2043–2047

MeSH term(s)	Humans ; Canagliflozin/therapeutic use ; Kidney ; Cardiovascular System ; Renal Insufficiency, Chronic/complications ; Renal Insufficiency, Chronic/drug therapy ; Renal Insufficiency, Chronic/chemically induced ; Peripheral Arterial Disease/complications ; Peripheral Arterial Disease/drug therapy ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/chemically induced ; Cardiovascular Diseases/complications ; Cardiovascular Diseases/drug therapy ; Cardiovascular Diseases/prevention & control
Chemical Substances	Canagliflozin (0SAC974Z85)
Language	English
Publishing date	2023-04-24
Publishing country	England
Document type	Letter ; Research Support, Non-U.S. Gov't
ZDB-ID	1454944-x
ISSN	1463-1326 ; 1462-8902
ISSN (online)	1463-1326
ISSN	1462-8902
DOI	10.1111/dom.15065
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5442: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials.

Sridhar, Vikas S / Neuen, Brendon L / Fletcher, Robert A / Slee, April / Ang, Fernando G / Rapattoni, Wally / Arnott, Clare / Cherney, David Z / Perkovic, Vlado / Wheeler, David C / Levin, Adeera

Diabetes, obesity & metabolism

2023 Volume 25, Issue 8, Page(s) 2331–2339

Abstract: Aim: In the CANVAS Program and CREDENCE trials, the sodium glucose co-transporter 2 inhibitor canagliflozin reduced the risk of cardiovascular and kidney events in patients with type 2 diabetes. The current study analysed a pooled population to ... ...

Abstract	Aim: In the CANVAS Program and CREDENCE trials, the sodium glucose co-transporter 2 inhibitor canagliflozin reduced the risk of cardiovascular and kidney events in patients with type 2 diabetes. The current study analysed a pooled population to ascertain the kidney protection provided by canagliflozin across the full spectrum of kidney parameters. Methods: This post-hoc pooled analysis of the CANVAS Program (N = 10 142) and CREDENCE trial (N = 4401), assessed the risk of the primary kidney composite (doubling of serum creatinine, end-stage kidney disease, renal death), in all patients and subgroups defined by baseline estimated glomerular filtration rate (<30, 30 to <45, 45 to <60 and ≥60 ml/min/1.73 m Results: In the overall population, the risk for the primary kidney composite outcome was 37% lower in the canagliflozin group versus placebo (HR: 0.63; 95% CI: 0.53, 0.77; p < .001). There was no evidence of heterogeneity in the kidney protective effects of canagliflozin across a range of kidney risks when stratified by baseline estimated glomerular filtration rate, albuminuria or KDIGO risk category (all p Conclusions: These results emphasize a critical role of canagliflozin in kidney protection across a broad spectrum of participants with type 2 diabetes with varying levels of kidney function.
MeSH term(s)	Humans ; Canagliflozin/therapeutic use ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/chemically induced ; Albuminuria/prevention & control ; Albuminuria/drug therapy ; Cardiovascular Diseases/epidemiology ; Kidney ; Sodium-Glucose Transporter 2 Inhibitors/adverse effects
Chemical Substances	Canagliflozin (0SAC974Z85) ; Sodium-Glucose Transporter 2 Inhibitors
Language	English
Publishing date	2023-05-15
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1454944-x
ISSN	1463-1326 ; 1462-8902
ISSN (online)	1463-1326
ISSN	1462-8902
DOI	10.1111/dom.15112
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5442: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE.

Tsoukas, Michael A / Woo, Vincent / Tobe, Sheldon W / Slee, April / Rapattoni, Wally / Ang, Fernando G / Seufert, Jochen / Neuen, Brendon L / Arnott, Clare / Mahaffey, Kenneth W / Wheeler, David C

Diabetes, obesity & metabolism

2023 Volume 25, Issue 7, Page(s) 2038–2042

MeSH term(s)	Humans ; Canagliflozin/therapeutic use ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Kidney ; Cardiovascular System ; Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/prevention & control
Chemical Substances	Canagliflozin (0SAC974Z85)
Language	English
Publishing date	2023-04-04
Publishing country	England
Document type	Letter ; Research Support, Non-U.S. Gov't
ZDB-ID	1454944-x
ISSN	1463-1326 ; 1462-8902
ISSN (online)	1463-1326
ISSN	1462-8902
DOI	10.1111/dom.15057
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5442: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial.

Sharma, Abhinav / Marques, Pedro / Neuen, Brendon L / Fletcher, Robert A / Slee, April / Rapattoni, Wally / Ang, Fernando G / Arnott, Clare / Levin, Adeera / Verma, Subodh / Perkovic, Vlado / Mahaffey, Kenneth W

Diabetes, obesity & metabolism

2023 Volume 26, Issue 2, Page(s) 758–762

MeSH term(s)	Humans ; Canagliflozin/therapeutic use ; Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/prevention & control ; Cardiovascular System ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Heart Failure/drug therapy ; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use ; Clinical Trials as Topic
Chemical Substances	Canagliflozin (0SAC974Z85) ; Sodium-Glucose Transporter 2 Inhibitors
Language	English
Publishing date	2023-10-26
Publishing country	England
Document type	Letter
ZDB-ID	1454944-x
ISSN	1463-1326 ; 1462-8902
ISSN (online)	1463-1326
ISSN	1462-8902
DOI	10.1111/dom.15340
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5442: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A retrospective observational population-based study to assess the prevalence and burden of illness of type 2 diabetes with an estimated glomerular filtration rate < 90 mL/min/1.73 m

Rapattoni, Wally / Zante, David / Tomas, Marko / Myageri, Varun / Golden, Shane / Grover, Prerna / Tehrani, Ali / Millson, Brad / Tobe, Sheldon W / Rose, Jennifer B

Diabetes, obesity & metabolism

2021 Volume 23, Issue 4, Page(s) 916–928

Abstract: Aim: To better understand the healthcare burden of people with type 2 diabetes (T2D) and estimated glomerular filtration rate (eGFR) < 90 mL/min/1.73 m: Materials and methods: We used administrative data to evaluate the prevalence of T2D, eGFR < 90 ... ...

Abstract	Aim: To better understand the healthcare burden of people with type 2 diabetes (T2D) and estimated glomerular filtration rate (eGFR) < 90 mL/min/1.73 m Materials and methods: We used administrative data to evaluate the prevalence of T2D, eGFR < 90 mL/min/1.73 m Results: While the prevalence of T2D in the general population aged ≥ 30 years in Ontario increased by 1.8% over a 5-year period (2011-2012 to 2015-2016), the prevalence of eGFR < 90 mL/min/1.73 m Conclusions: This real-world retrospective study highlights an increasing prevalence of T2D, eGFR < 90 mL/min/1.73 m
Language	English
Publishing date	2021-01-13
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1454944-x
ISSN	1463-1326 ; 1462-8902
ISSN (online)	1463-1326
ISSN	1462-8902
DOI	10.1111/dom.14294
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5442: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice.

Woo, Vincent / Bell, Alan / Clement, Maureen / Noronha, Luis / Tsoukas, Michael A / Camacho, Fernando / Traina, Shana / Georgijev, Natasha / Culham, Matthew D / Rose, Jennifer B / Rapattoni, Wally / Bajaj, Harpreet S

Diabetes, obesity & metabolism

2018 Volume 21, Issue 3, Page(s) 691–699

Abstract: Aim: There is limited information concerning the effects of canagliflozin (CANA), a sodium-glucose co-transporter 2 inhibitor (SGLT2i) in a real-world clinical setting in Canada. CanCARE is a 12-month, prospective, observational analysis to demonstrate ... ...

Abstract	Aim: There is limited information concerning the effects of canagliflozin (CANA), a sodium-glucose co-transporter 2 inhibitor (SGLT2i) in a real-world clinical setting in Canada. CanCARE is a 12-month, prospective, observational analysis to demonstrate the effectiveness and safety of CANA in usual clinical practice in Canada. Materials and methods: SGLT2i-naïve adult patients with type 2 diabetes mellitus (T2DM) (n = 527) on a stable antihyperglycemic agent (AHA) regimen with glycated hemoglobin (A1C) ≥ 7%, an estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m Results: Significant improvement from baseline in mean HbA1c levels were observed at 6 months (-0.90%; 95% CI, -1.02, -0.78) and at 12 months (-1.04%; 95% CI, -1.15, -0.92), regardless of duration of diabetes or background AHA treatment regimen. Similarly, significant decreases in systolic blood pressure (-4.65 mm Hg); body weight (-3.24 kg), waist circumference (-2.91 cm) and body mass index (-1.15 kg/m Conclusion: CANA provided sustained clinically meaningful improvements in cardiometabolic parameters in this study in a real-world setting, confirming findings from randomized controlled trials.
MeSH term(s)	Adult ; Aged ; Canada ; Canagliflozin/adverse effects ; Canagliflozin/therapeutic use ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/epidemiology ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Electronic Health Records/statistics & numerical data ; Female ; General Practice/statistics & numerical data ; Humans ; Male ; Middle Aged ; Registries ; Treatment Outcome
Chemical Substances	Canagliflozin (0SAC974Z85)
Language	English
Publishing date	2018-12-05
Publishing country	England
Document type	Journal Article ; Multicenter Study ; Observational Study ; Research Support, Non-U.S. Gov't
ZDB-ID	1454944-x
ISSN	1463-1326 ; 1462-8902
ISSN (online)	1463-1326
ISSN	1462-8902
DOI	10.1111/dom.13573
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5442: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito